Clinigen Group (LON:CLIN)‘s stock had its “add” rating reissued by Numis Securities in a note issued to investors on Wednesday. They currently have a GBX 1,208 ($16.38) price objective on the stock. Numis Securities’ target price suggests a potential upside of 14.07% from the company’s previous close.
A number of other research analysts have also weighed in on CLIN. Peel Hunt restated a “buy” rating and issued a GBX 1,350 ($18.31) price objective on shares of Clinigen Group in a report on Wednesday. N+1 Singer restated a “buy” rating and issued a GBX 1,225 ($16.61) price objective on shares of Clinigen Group in a report on Wednesday, November 29th. Berenberg Bank assumed coverage on Clinigen Group in a report on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($16.27) price objective on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and issued a GBX 1,360 ($18.44) price objective on shares of Clinigen Group in a report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Clinigen Group currently has a consensus rating of “Buy” and an average price target of GBX 1,222.17 ($16.57).
Shares of Clinigen Group (CLIN) traded up GBX 9 ($0.12) during mid-day trading on Wednesday, reaching GBX 1,059 ($14.36). The company’s stock had a trading volume of 664,427 shares, compared to its average volume of 372,742. The stock has a market cap of $1,300.00 and a price-to-earnings ratio of 35,300.00. Clinigen Group has a 12 month low of GBX 751.50 ($10.19) and a 12 month high of GBX 1,187 ($16.10).
TRADEMARK VIOLATION NOTICE: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3146182/clinigen-group-clin-rating-reiterated-by-numis-securities.html.
About Clinigen Group
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.